Tags

Type your tag names separated by a space and hit enter

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
J Natl Compr Canc Netw 2019; 17(6):650-661JN

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Authors+Show Affiliations

1Memorial Sloan Kettering Cancer Center.2Robert H. Lurie Comprehensive Cancer Center of Northwestern University.3Massachusetts General Hospital Cancer Center.4Stanford Cancer Institute.5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.6Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.7University of Wisconsin Carbone Cancer Center.8Moffitt Cancer Center.9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.10The University of Texas MD Anderson Cancer Center.11Huntsman Cancer Institute at the University of Utah.12Mayo Clinic Cancer Center.3Massachusetts General Hospital Cancer Center.13Roswell Park Comprehensive Cancer Center.14University of Michigan Rogel Cancer Center.15Duke Cancer Institute.16Fox Chase Cancer Center.17Consultant.18Dana-Farber/Brigham and Women's Cancer Center.19O'Neal Comprehensive Cancer Center at UAB.20City of Hope National Medical Center.21University of Colorado Cancer Center.22Vanderbilt-Ingram Cancer Center.23UC San Diego Moores Cancer Center.24Yale Cancer Center/Smilow Cancer Hospital.25University of Washington/Seattle Cancer Care Alliance.19O'Neal Comprehensive Cancer Center at UAB.26The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.27Fred & Pamela Buffett Cancer Center; and.28National Comprehensive Cancer Network.28National Comprehensive Cancer Network.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31200358

Citation

Zelenetz, Andrew D., et al. "NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 17, no. 6, 2019, pp. 650-661.
Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650-661.
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., ... Sundar, H. (2019). NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal of the National Comprehensive Cancer Network : JNCCN, 17(6), pp. 650-661. doi:10.6004/jnccn.2019.0029.
Zelenetz AD, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. PubMed PMID: 31200358.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. AU - Zelenetz,Andrew D, AU - Gordon,Leo I, AU - Abramson,Jeremy S, AU - Advani,Ranjana H, AU - Bartlett,Nancy L, AU - Caimi,Paolo F, AU - Chang,Julie E, AU - Chavez,Julio C, AU - Christian,Beth, AU - Fayad,Luis E, AU - Glenn,Martha J, AU - Habermann,Thomas M, AU - Lee Harris,Nancy, AU - Hernandez-Ilizaliturri,Francisco, AU - Kaminski,Mark S, AU - Kelsey,Christopher R, AU - Khan,Nadia, AU - Krivacic,Susan, AU - LaCasce,Ann S, AU - Mehta,Amitkumar, AU - Nademanee,Auayporn, AU - Rabinovitch,Rachel, AU - Reddy,Nishitha, AU - Reid,Erin, AU - Roberts,Kenneth B, AU - Smith,Stephen D, AU - Snyder,Erin D, AU - Swinnen,Lode J, AU - Vose,Julie M, AU - Dwyer,Mary A, AU - Sundar,Hema, PY - 2019/6/15/entrez PY - 2019/6/15/pubmed PY - 2019/6/15/medline SP - 650 EP - 661 JF - Journal of the National Comprehensive Cancer Network : JNCCN JO - J Natl Compr Canc Netw VL - 17 IS - 6 N2 - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL. SN - 1540-1413 UR - https://www.unboundmedicine.com/medline/citation/31200358/NCCN_Guidelines_Insights:_B-Cell_Lymphomas,_Version_3.2019 L2 - https://jnccn.org/doi/10.6004/jnccn.2019.0029 DB - PRIME DP - Unbound Medicine ER -